Design and validation of the first family of photo-activatable ligands for melatonin receptors

Gloria, S.-B.; Serra, C.; Lyons, D.; Piggins, H.; Jockers, R.; Llebaria, A.

doi:10.1101/2022.05.05.490738

Home/Archive/bioRxiv

bioRxiv · 10.1101/2022.05.05.490738

Design and validation of the first family of photo-activatable ligands for melatonin receptors

Gloria, S.-B.·Serra, C.·Lyons, D.·Piggins, H.·Jockers, R.·Llebaria, A.

View original source ↗Export metadata ↓

Abstract

Melatonin is a neurohormone released in a circadian manner with peak levels during the night. In mammals, melatonin mediates its effects mainly through G protein-coupled MT1 and MT2 receptors. Drugs acting on melatonin receptors are indicated for circadian rhythm- and sleep-related disorders and major depression. Pharmacological tools to study the activation of these receptors with high temporal resolution are lacking. Here, we synthesized a family of light-activatable caged melatonin compounds by covalently attaching o-nitrobenzyl (o-NB) or coumarin photocleavable groups to the N-position of melatonin. All caged compounds showed the expected decrease in binding affinity for MT1 and MT2. Among them, the o-NB derivative MCS-0382 showed the best uncaging and biological properties upon light activation with a significant increase (2.5 log left-shift) in affinity and potency in melatonin receptor binding and signaling, respectively. Generation of biologically active melatonin from MCS-0382 was further demonstrated by its ability to modulate the excitation of SCN neurons in rat brain slices. MCS-0382 is now available to study melatonin effects in a temporally controlled manner in cellular and physiological settings.

Source connections

Published article ↗

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Gloria, S.-B., Serra, C., Lyons, D., Piggins, H., Jockers, R., Llebaria, A.. 2022-05-05. Design and validation of the first family of photo-activatable ligands for melatonin receptors. https://doi.org/10.1101/2022.05.05.490738

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

bioRxiv2023

Synthesis of water-soluble and gastrointestinal transit-resistant FA-FOS conjugate for targeted delivery to the colon: pharmacokinetics, pharmacodynamics, efficacy

Ferulic acid is known to be a water-insoluble compound present in many fruits and vegetables and is known to possess antioxidant, anti-cancer, and anti-inflammatory properties. They are quickly absorbed in the stomach and metabolized in the liver. Their colonic exposure is found to be low due to their quick absorption and metabolism in the upper gastrointestinal tract, and due to this reason, only a small fraction of FA found in a bound form is associated with the insoluble and soluble fiber of the food matrix reaching the colon. Here we describe the synthesis and characterization of ferulic acid (FA) bound to fructo oligosaccharide (FOS) rendering the resultant FA-FOS conjugate water soluble, resistant to gastrointestinal digestion and absorption, along with the capability to deliver a therapeutically meaningful dose of FA to the large intestine. Free FA is released from FA-FOS conjugate by the digestive action of gut microflora, and the pharmacokinetic profile and pharmacodynamics are evaluated in a rat model. The efficacy of FA-FOS conjugate in the delivery of FA to the large intestine and its accumulation in tumours were evaluated in colitis induced colon cancer model and their efficacy through plasma bioavailability is determined in xenograft mice model carrying tumour from human colon cancer cells. The accumulation of FA derived from FA-FOS conjugate in the tumour was demonstrated by the MALDI imaging technique. The major metabolites of FA-FOS conjugate in plasma were determined through a data-dependent MS/MS experiment of precursor ion scan, utilizing triple quad (QTRAP) equipped LC-MS.

pharmacology and toxicology↗